I have a new biomedical science column called Lab Dish over at STAT News.
Every month or so I will write an opinion piece, often focused on new developments in the field.
Lab Dish, Knoepfler column
A lab dish of 293T cells.
What’s the focus of Lab Dish?
As a cell biology professor, I’ve made a conscious decision to write beyond the usual academic stuff (paper, grants, etc.), including here on The Niche. It’s part of my educational outreach.
In addition, I’ve occasionally written pieces for popular media outlets like Wired and STAT News.
Lab Dish seemed like an appropriate name given what we have in mind.
The focus will be on biologics research (including stem cells and regeneration), related biotechs, gene editing, policy issues, and clinical trials. I will also cover important developments at the FDA, especially its CBER branch.
My first column at STAT News
Check out my first Lab Dish column that was published yesterday: “How will the Center for Biologics Evaluation and Research change under RFK Jr.?”
The subtitle is: “A recent FDA CBER workshop provided clues.” The meeting was an interesting combination of reassurance that CBER hadn’t totally changed (yet) along with some indications that big changes are likely coming soon.
Why team up with STAT News?
In writing The Niche since 2010, I’ve seen STAT News relatively quickly become one of the go-to biomedical sciences resources. I regularly find myself reading and then writing about articles over there. Of course, there are other great biomedical media outlets too. I also enjoy MIT Technology Review including in particular articles by Antonio Regalado and in recent years by Jessica Hamzelou.
STAT News just seemed like a great fit and I like their approach to science journalism.
Follow along as I continue writing over at STAT. Please consider subscribing to STAT+ too. You can get started with just $20.
Related Posts